Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Lluch

Showing results (121-130 of 186) with videos related to

Pageof 19
Sort By:
Molecular Cancer Therapeutics|May 15, 2020
Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast CancerSandra Zazo, Paula González-Alonso, Ester Martín-Aparicio, et al.
Breast Cancer Research : BCR|November 7, 2013
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysisBella Pajares, Marina Pollán, Miguel Martín, et al.
Molecular Cancer Research : MCR|March 29, 2022
mTOR Inhibition and T-DM1 in HER2-Positive Breast CancerDavid Casadevall, Anna Hernández-Prat, Sara García-Alonso, et al.
International Journal of Radiation Oncology, Biology, Physics|March 15, 2018
Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 TrialYoussef H Zeidan, Joyce G Habib, Lieveke Ameye, et al.
Oncotarget|July 5, 2022
Role of germline variants in the metastasis of breast carcinomasÁngela Santonja, Aurelio A Moya-García, Nuria Ribelles, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 18, 2009
Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)Joan Albanell, Xavier Andreu, María José Calasanz, et al.
Plos One|June 16, 2015
Patterns of HER2 Gene Amplification and Response to Anti-HER2 TherapiesRocio Vicario, Vicente Peg, Beatriz Morancho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2016
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST SubstudyMeritxell Bellet, Kathryn P Gray, Prudence A Francis, et al.
International Journal of Molecular Sciences|July 29, 2023
Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase InhibitorsJesús Fuentes-Antrás, Ana Martínez-Rodríguez, Kissy Guevara-Hoyer, et al.
European Journal of Cancer Care|June 25, 2020
Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)Eva M Ciruelos, Alvaro Montaño, César A Rodríguez, et al.
Pageof 19

Showing results (121-130 of 186) with videos related to

Sort By:
Pageof 19
Molecular Cancer Therapeutics|May 15, 2020
Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast CancerSandra Zazo, Paula González-Alonso, Ester Martín-Aparicio, et al.
Breast Cancer Research : BCR|November 7, 2013
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysisBella Pajares, Marina Pollán, Miguel Martín, et al.
Molecular Cancer Research : MCR|March 29, 2022
mTOR Inhibition and T-DM1 in HER2-Positive Breast CancerDavid Casadevall, Anna Hernández-Prat, Sara García-Alonso, et al.
International Journal of Radiation Oncology, Biology, Physics|March 15, 2018
Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 TrialYoussef H Zeidan, Joyce G Habib, Lieveke Ameye, et al.
Oncotarget|July 5, 2022
Role of germline variants in the metastasis of breast carcinomasÁngela Santonja, Aurelio A Moya-García, Nuria Ribelles, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 18, 2009
Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)Joan Albanell, Xavier Andreu, María José Calasanz, et al.
Plos One|June 16, 2015
Patterns of HER2 Gene Amplification and Response to Anti-HER2 TherapiesRocio Vicario, Vicente Peg, Beatriz Morancho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2016
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST SubstudyMeritxell Bellet, Kathryn P Gray, Prudence A Francis, et al.
International Journal of Molecular Sciences|July 29, 2023
Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase InhibitorsJesús Fuentes-Antrás, Ana Martínez-Rodríguez, Kissy Guevara-Hoyer, et al.
European Journal of Cancer Care|June 25, 2020
Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)Eva M Ciruelos, Alvaro Montaño, César A Rodríguez, et al.
Pageof 19